Hereditary Pheochromocytoma Assessment of Tumour Immunologies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRadboud University Medical Center

About this trial

In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.

Eligibility criteria

Qualifiers

Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.

OR patients with mutations which predispose for the development of PPGL.

Aged > 18 years.

Confirmed PPGL on pathology.

Disqualifiers

Unable to provide informed consent.

Active inflammatory or infectious comorbidities.

Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas).

Using medication interfering with the immune system

Trial design

Treatments tested in this trial

  • Venepuncture
  • Venepuncture

Treatment groups

200 Participants
are divided into 4 treatment groups